Home > Journals > Minerva Dental and Oral Science > Past Issues > Minerva Stomatologica 2014 March;63(3) > Minerva Stomatologica 2014 March;63(3):59-67

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

ORIGINAL ARTICLES   

Minerva Stomatologica 2014 March;63(3):59-67

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

Immunoexpression of angiogenesis and proliferation markers in patients treated with cyclosporin A

Afonso M. 1, Perrotti V. 2, Rapani M. 2, Iaculli F. 2, Piccirilli M. 2, Onuma T. 3, Shibli J. A. 3, De Oliveira Bello V. 4, Sposto M. R. 1, Artese L. 2

1 Department of Diagnosis and Oral Surgery Araraquara Dental School, UNESP Araraquara, SP, Brazil; 2 Department of Medical, Oral and Biotechnological Sciences Dental School, University of Chieti‑Pescara Chieti, Italy; 3 Department of Periodontology Dental Research Division, Guarulhos University Guarulhos, SP, Brazil; 4 Kidney Transplant Unit Base Hospital, Brasilia, Brazil


PDF


Aim: In the present immunohistochemical study, the expression of vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67 in the gingival tissues of renal transplant patients treated with cyclosporin A was assessed. Gingival overgrowth (GO) frequently occurs in transplant patients receiving immunosuppressive drugs such as cyclosporine and this gingival inflammation might play an important role in the pathogenesis of drug-induced GO.
Methods: Twenty-eight human gingival biopsies were taken from healthy patients with chronic periodontitis (N.=14 control group), and from renal transplant recipients treated with cyclosporin A (N.=14 test group). The retrieved specimens were immunohistochemically processed and stained for vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67.
Results: The levels of vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67 were found to be significantly different among groups (P>0.001), with patients treated with cyclosporin A showing higher levels of all the analyzed markers compared to control group.
Conclusion: In summary, the data from this pilot study suggests that the investigated factors have a role in the inflammation processes associated to immunosuppressive therapy. However, further studies with a larger sample population need to be conducted for an exhaustive knowledge of the mechanisms leading to GO.

top of page